Trial Information

Late Effects of Treatment in Survivors of Pediatric Sarcomas

Childhood cancers mark a relatively infrequent disease entity with an annual age adjusted
rate in children age 0-14 years of 14 per 100,000. Over the last 30 years a striking
increase in survival due to improved diagnosis and aggressive treatment approaches has
vastly enhanced the outlook in this patient population. 75% of children under 15 years age
of can be expected to survive the diagnosis of cancer for more than 5 years. However,
reports of improved survival have been followed by increasing awareness of a multitude of
long-term treatment-related side effects, in addition to an overall death rate 9.6 times
higher than in the sex- and age-matched general population. Over the last 35 years,
patients with pediatric sarcomas have been treated in the Pediatric Oncology Branch (POB) of
the National Cancer Institute. Since 1971 adriamycin and cyclophosphamide in escalating
doses have been incorporated in all multimodality treatment protocols. Ifosfamide became an
integral part of therapy in 1986. The survival rate of patients with these diseases has
improved over this period of time. Accordingly there exists a group of long-term survivors
of therapy employed in a series of POB sarcoma protocols who represent a valuable source of
information on treatment-associated late-effects, e.g. cardiotoxicity, gonadal dysfunction,
growth delay and stress-related neuroendocrine abnormalities. In addition there may be
evaluable rehabilitative impairments and alterations in psychosocial behavior that may only
manifest over time, and prove to be characteristic for this population. This protocol will
systematically enumerate and describe the incidence and extent of treatment related
long-term toxicities in this patient population.